Pradaxa Safety as Expected in New FDA Study

The U.S. Food and Drug Administration released the results of a study on the safety and efficacy of dabigatran (Pradaxa) in 134,000 Medicare recipients with nonvalvular atrial fibrillation. New users of dabigatran — versus warfarin (blood thinner) — had reduced risks of ischemic stroke, intracranial hemorrhage and death. The risk of major gastrointestinal (GI) bleeding was higher with dabigatran, but there was no difference in the risk of heart attack. Via Medpage. Posted May 13, 2014.

–Alanna McCatty


Alanna McCatty

Alanna McCatty

Alanna McCatty is founder and CEO of McCatty Scholars, an organization that devises and implements financial literacy programs for students to combat the nationwide issue of the loss of educational opportunity due to the ramifications of burdensome student debt. At MedShadow, she reports on new findings and research on the side effects of prescription drugs. She is a graduate of Pace University.


Did you find this article helpful?

No votes so far! Be the first to rate this post.


Latest News

Effects of Vitamin D and Antibiotics during Pregnancy

Effects of Vitamin D and Antibiotics during Pregnancy

A new study out today on Vitamin D and pregnancy plus two more studies on how drugs and supplements given to pregnant women affect the fetus and the offspring for years to come.  Be well.   Bone Density Taking higher doses of Vitamin D during pregnancy showed a correlation with…

Belviq, ActiPatch, Free Samples, Dollar Tree Drugs

Belviq, ActiPatch, Free Samples, Dollar Tree Drugs

We knew it was too good to be true – free and cheap drugs aren’t worth it. Also, taking a magic pill to lose weight could give you cancer (!). One ray of sunshine: a pain therapy device using shortwave is now available over-the-counter. Have a lovely Valentine’s Day! Be…

  • Advertisement